IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit . NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET.
纽约，2024年12月2日（环球新闻通讯）-- in8bio公司（纳斯达克代码：INAB）是一家临床阶段的生物制药公司，专注于开发创新的伽马-德尔塔电芯疗法，今天宣布首席执行官兼联合创始人William Ho将在2024年12月3日（星期二）上午10:30（东部时间）出席NobleCon20 - Noble资本市场第二十届年度新兴成长股权会议并进行演讲。
A high-definition video webcast of the presentation will be available the following day on the Company's website and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website: and on Channelchek the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event.
演讲的高清直播将在次日通过公司的官方网站提供，同时作为Noble资本市场会议网站上的完整演讲目录的一部分，此外在Noble公司创建的投资者门户Channelchek上也将可用。直播将在会议结束后90天内存档于公司的官方网站、NobleCon网站和Channelchek.com上。
About IN8bio
关于in8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit .
in8bio是一家临床阶段的生物制药公司，开发针对癌症患者的伽马-德尔塔电芯基础免疫疗法。伽马-德尔塔电芯是一种特殊的电芯群体，具有独特的特性，包括区分健康与疾病组织的能力。公司的主要项目INb-400正在进行胶质母细胞瘤（GBM）的二期临床试验。其他项目包括针对实质性和血液肿瘤的一级试验，包括INb-200针对胶质母细胞瘤和INb-100针对接受移植的血液恶性肿瘤患者。有关in8bio的更多信息，请访问。
Investors and Corporate Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
投资者和企业联系人：
格伦·舒尔曼，药学博士，公共卫生硕士
203.494.7411
gdschulman@IN8bio.com
Patrick McCall, CFO
IN8bio, Inc
pfmccall@IN8bio.com
帕特里克·麦克考，首席财务官
IN8bio，Inc
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
媒体联系
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
